QUANTIFAST
LIVE

Serial Number

79034206

Owner

QIAGEN GMBH

Attorney

Victoria Friedman

Filing Date

Nov 15, 2006

Add to watchlist:

No watchlists yet
View on USPTO

QUANTIFAST Trademark

Serial Number: 79034206 • Registration: 3524308

QUANTIFAST is a trademark filed by QIAGEN GMBH on November 15, 2006. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

QIAGEN GMBH (210 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

Trademark Details

Filing Date

November 15, 2006

Registration Date

October 28, 2008

Published for Opposition

August 12, 2008

Goods & Services

Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes, non-medical reagents and solvents for scientific, and/or medical research use for [ sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, ] duplicating and/or analytic methods for biopolymers, in particular nucleic acids, [ proteins, macromolecules ] and biologically active substances, in particular reagents and solvents for nucleic acid amplification, in particular by polymerase chain reaction (PCR); kits comprising chemicals for [ sample preparation, modification and manipulation of cells and ] for marking, [ separating, isolating, purifying, ] duplicating and/or for the analysis of biopolymers, in particular nucleic acids, [ proteins, macromolecules and biologically active substances, in particular nucleic acids ] of biological or biochemical sample material, in particular comprising chemicals for reagents and solvents for nucleic acid amplification, in particular by polymerase chain reaction (PCR)

[ Scientific apparatuses, instruments and equipment and laboratory instruments and measuring apparatuses and instruments in particular for research, medical, diagnostic and analysis purposes, namely, disposable laboratory articles, namely, vessels plastic vessels, sample storage vessels, reaction and collection vessels and plates, multi-well plates, tips, including filter tips and dispenser tips, pipette tips and tip boxes, tubes, microtubes and tubes for PCR and micro centrifuges and micro-injection, capillaries, curvettes, spin columns, cartridges and columns filed with chromatographic material for the separation, purification, and isolation of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR); racks and holders for samples storage vessels, tubes, syringes and tips; magnetic beads, membranes and silica material for nucleic acid isolation and purification, sample presentation devices, mircroarrays, chips, MALDI-MS presentation devices; laboratory robots, robotic workstations and systems and laboratory incubators for diagnostic, clinical and research applications for the preparation, modification, isolation, crystallization, handling, amplification and manipulation of samples and for the marking, separation, isolation, purification, reproduction and analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR); laboratory apparatuses and equipment for dosage, dispensing, transferring, temperature equalizing, agitating, mixing, diluting, concentrating and separating of liquids; MALDI- apparatuses, workstations for reading and handling multi-well plates for the analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR); cyclers, thermocyclers, lysis apparatuses, disrupters, physico-chemical, bio-chemical, optical and electronic analysis apparatus and equipment, in particular photometers, spectrophotometers, optical scanners for detection of fluorescence and colorimetric signals; apparatuses for processing cells or liquids containing cells in particular electroporators, electrofusion apparatuses, micro injectors and micro manipulators; vacuum chambers for chromatography, purification, separation and characterization of natural and synthetic biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material; centrifuges; vacuum systems for laboratory use, vacuum concentrators; centrifugal concentrators; rotors for laboratory centrifuges and vacuum concentrators, mixers; mechanical, electronical and automatical pipettes and dispensers for dispensing liquid for laboratory research and analysis purposes ]

Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, in particular for [ sample preparation, modification and manipulation of cells and for ] marking, [ separating, isolating, purifying, ] duplicating and/or for the analysis of biopolymers, in particular nucleic acids, [ proteins, macromolecules ] and biologically active substances, in particular preparations for medical and veterinary purposes for reagents and solvents for nucleic acid amplification, in particular by polymerase chain reaction (PCR); chemical, biochemical and biotechnological preparations, in particular reagents and solvents for [ sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, duplicating and/or ] analysis methods for biopolymers, in particular nucleic acids, [ proteins, macromolecules ] and biologically active substances for diagnostic medical use, and clinical use in particular reagents and solvents for nucleic acid amplification, in particular by polymerase chain reaction (PCR); kits containing preparations for medical and veterinary diagnostic purposes, in particular for [ sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, ] duplicating and/or for the analysis of biopolymers, in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR)

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 20, 2025 NREP
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Jul 17, 2019 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 24, 2019 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Oct 24, 2018 NA71
REGISTERED-SEC.71 ACCEPTED
Oct 24, 2018 71AG
TEAS SECTION 71 RECEIVED
Oct 16, 2018 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Oct 28, 2017 REM4
INTERNATIONAL REGISTRATION RENEWED
Dec 1, 2016 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Sep 11, 2015 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Aug 18, 2015 INPS
INVALIDATION PROCESSED
Aug 18, 2015 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 30, 2015 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Oct 30, 2014 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Oct 30, 2014 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 30, 2014 APRE
TEAS SECTION 71 & 15 RECEIVED
Oct 22, 2014 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Dec 13, 2013 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 5, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 5, 2009 FICS
FINAL DISPOSITION PROCESSED
Feb 5, 2009 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 28, 2009 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 28, 2008 R.PR
PUBLISHED FOR OPPOSITION
Aug 12, 2008 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 7, 2008 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 24, 2008 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 24, 2008 OPNR
NOTICE OF PUBLICATION
Jul 23, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 7, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 3, 2008 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 3, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 3, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 3, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 3, 2008 CNEA
EXAMINER'S AMENDMENT ENTERED
Jun 20, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 20, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 20, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 20, 2008 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Feb 7, 2008 GPRN
PRIORITY ACTION E-MAILED
Feb 7, 2008 GPRA
PRIORITY ACTION WRITTEN
Feb 7, 2008 CPRA
EXAMINER'S AMENDMENT ENTERED
Jan 30, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 30, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 30, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 30, 2008 CNEA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 23, 2008 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 23, 2008 REAP
NON-FINAL ACTION MAILED
Nov 27, 2007 CNRT
NON-FINAL ACTION WRITTEN
Nov 27, 2007 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Nov 27, 2007 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 20, 2007 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 5, 2007 PREV
ASSIGNED TO LIE
Oct 5, 2007 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 6, 2007 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2007 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2007 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 29, 2007 TROA
REFUSAL PROCESSED BY IB
Mar 29, 2007 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 8, 2007 RFCS
REFUSAL PROCESSED BY MPU
Mar 8, 2007 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 6, 2007 RFCR
NON-FINAL ACTION WRITTEN
Mar 5, 2007 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Mar 2, 2007 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 1, 2007 RFCR
NON-FINAL ACTION WRITTEN
Feb 28, 2007 CNRT
ASSIGNED TO EXAMINER
Feb 26, 2007 DOCK
NEW APPLICATION ENTERED
Feb 23, 2007 NWAP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 22, 2007 REPR